Fluvoxamine: an open pilot study in moderately obese female patients suffering from atypical eating disorders and episodes of bingeing.

Abstract

The results of a small pilot study using Fluvoxamine (Faverin) in the treatment of non-vomiting bingeing female patients and women with bulimia nervosa is presented. Ten non-vomiting subjects and six with bulimia nervosa were treated on an open basis with Fluvoxamine 100-200 mg daily. Assessment was made using established questionnaires for severity of eating disorder and abnormality of mood. Five non-vomiting patients and three with bulimia nervosa completed the study. Non-vomiters showed a significant weight loss; a significant reduction in number of binges; a significant reduction in the scores on the BITE and the EAT; and a significant reduction in anxiety. Those with bulimia nervosa had a significant reduction in hunger and a reduction in depression which tended towards significance. Firm conclusions cannot be drawn from this study as it is an open pilot study of a small number of women. However, the results indicate that Fluvoxamine may have a role in the treatment of eating disorders where bingeing is a prominent symptom and that further research would be valuable. Comments are also made on the usefulness of various questionnaires designed to assess eating disorders.

• Authors: H M Gardiner, C P Freeman, D K Jesinger, S A Collins
• Journal: International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (Int J Obes Relat Metab Disord) Vol. 17 Issue 5 Pg. 301-5 (May 1993) England
• PMID: 8389340 (Publication Type: Journal Article)

Chemical References

• Fluvoxamine

Topics

• Adolescent
• Adult
• Bulimia (complications, drug therapy)
• Depression (drug therapy)
• Feeding and Eating Disorders (complications, drug therapy)
• Female
• Fluvoxamine (adverse effects, therapeutic use)
• Humans
• Obesity (complications, drug therapy)
• Surveys and Questionnaires
• Vomiting
• Weight Loss